92 related articles for article (PubMed ID: 6769937)
1. Pergolide mesylate: a potent day-long inhibitor of prolactin in rhesus monkeys and patients with Parkinson's disease.
Kleinberg DL; Lieberman A; Todd J; Greising J; Neophytides A; Kupersmith M
J Clin Endocrinol Metab; 1980 Jul; 51(1):152-4. PubMed ID: 6769937
[TBL] [Abstract][Full Text] [Related]
2. Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease.
Bell RD; Carruth A; Rosenberg RN; Boyar RM
J Clin Endocrinol Metab; 1978 Oct; 47(4):807-11. PubMed ID: 45469
[TBL] [Abstract][Full Text] [Related]
3. Pergolide mesylate: its effects on circulating anterior pituitary hormones in man.
Perryman RL; Rogol AD; Kaiser DL; MacLeod RM; Thorner MO
J Clin Endocrinol Metab; 1981 Oct; 53(4):772-8. PubMed ID: 6793609
[TBL] [Abstract][Full Text] [Related]
4. Potent 48 hours inhibition of prolactin secretion by pergolide in hyperprolactinaemic women.
L'Hermite M; Debusschere P
Acta Endocrinol (Copenh); 1982 Dec; 101(4):481-3. PubMed ID: 7158225
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hyperprolactinaemia with pergolide mesylate: acute effects and preliminary evaluation of long-term treatment.
Franks S; Horrocks PM; Lynch SS; Butt WR; London DR
Lancet; 1981 Sep; 2(8248):659-61. PubMed ID: 6116045
[TBL] [Abstract][Full Text] [Related]
6. The effects of pergolide on the cardiovascular system of 40 patients with Parkinson's disease.
Leibowitz M; Lieberman AN; Neophytides A; Gopinathan G; Goldstein M
Adv Neurol; 1983; 37():121-30. PubMed ID: 6858770
[TBL] [Abstract][Full Text] [Related]
7. Pergolide, a potent long-acting dopamine-receptor agonist.
Lemberger L; Crabtree R; Callaghan JT
Clin Pharmacol Ther; 1980 May; 27(5):642-51. PubMed ID: 7189453
[TBL] [Abstract][Full Text] [Related]
8. Effect of pergolide mesylate, an ergoline, in animal models of Parkinson's disease: implications for therapy.
Koller WC; Diamond BI; Weiner WJ; Nausieda PA; Klawans HL
Trans Am Neurol Assoc; 1979; 104():161-4. PubMed ID: 553398
[No Abstract] [Full Text] [Related]
9. A 6-month trial of pergolide mesylate in the treatment of idiopathic Parkinson's disease.
Klawans HL; Tanner CM; Glatt S; Goetz CG
Adv Neurol; 1983; 37():75-83. PubMed ID: 6344592
[No Abstract] [Full Text] [Related]
10. Pergolide and lisuride in advanced Parkinson's disease.
Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Goldstein M
Adv Neurol; 1984; 40():503-7. PubMed ID: 6695627
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hyperprolactinaemic patients with pergolide.
L'Hermite M; Debusschere PM; Gillet C; Deschepper C
Acta Endocrinol (Copenh); 1983 Aug; 103(4):441-5. PubMed ID: 6412498
[TBL] [Abstract][Full Text] [Related]
12. Pergolide in Parkinson's disease.
Goetz CG; Tanner CM; Glantz R; Klawans HL
Arch Neurol; 1983 Dec; 40(13):785-7. PubMed ID: 6639407
[TBL] [Abstract][Full Text] [Related]
13. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Antonini A; Poewe W
Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
[TBL] [Abstract][Full Text] [Related]
14. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone.
Kleinberg DL; Boyd AE; Wardlaw S; Frantz AG; George A; Bryan N; Hilal S; Greising J; Hamilton D; Seltzer T; Sommers CJ
N Engl J Med; 1983 Sep; 309(12):704-9. PubMed ID: 6888442
[TBL] [Abstract][Full Text] [Related]
15. Pergolide mesylate inhibits exercise-induced prolactin release in man.
De Meirleir K; Baeyens L; L'Hermite M; L'Hermite-Balériaux M; Olbrecht J; Holmann W
Fertil Steril; 1985 Apr; 43(4):628-31. PubMed ID: 3987929
[TBL] [Abstract][Full Text] [Related]
16. Pergolide in the treatment of Parkinson's disease.
Mear JY; Barroche G; de Smet Y; Weber M; Lhermitte F; Agid Y
Neurology; 1984 Jul; 34(7):983-6. PubMed ID: 6539880
[TBL] [Abstract][Full Text] [Related]
17. Pergolide therapy in Parkinson's disease.
Jeanty P; Van den Kerchove M; Lowenthal A; De Bruyne H
J Neurol; 1984; 231(3):148-52. PubMed ID: 6481422
[TBL] [Abstract][Full Text] [Related]
18. The long-acting dopamine agonist pergolide mesylate for treatment of hyperprolactinaemia.
Bergh T; Nillius SJ; Wide L
Acta Eur Fertil; 1984; 15(6):421-4. PubMed ID: 6536135
[TBL] [Abstract][Full Text] [Related]
19. Reduction in size of prolactin-secreting tumours in men treated with pergolide.
Kendall-Taylor P; Hall K; Johnston DG; Prescott RW
Br Med J (Clin Res Ed); 1982 Aug; 285(6340):465-7. PubMed ID: 6809126
[TBL] [Abstract][Full Text] [Related]
20. Influence of thyroidectomy and prolactin suppression on the growth of N-nitrosomethylurea-induced rat mammary carcinomas.
Rose DP; Mountjoy KG
Cancer Res; 1983 Jun; 43(6):2588-91. PubMed ID: 6850579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
